Complete response of sunitinib therapy for renal cell cancer recurrence in the native kidney after renal transplantation: a case report

Abstract

BackgroundNo case report has yet shown that sunitinib therapy for the postoperative recurrence of renal cancer in a native kidney after renal transplantation can achieve complete response (CR).Case presentationA tumor was detected in the right native kidney of a 35-year-old Japanese male 10 years after renal transplantation. A tumor thrombus that reached the atrium was detected, which suggested cT3cN0M0. Because of the risk of perioperative complications, preoperative therapy with sunitinib was selected and 8 courses were administered. The size of the primary tumor was reduced by 33%, while that of the tumor thrombus was decreased by 39.5%.Right nephrectomy and removal of the tumor thrombus were then performed. Contrast-enhanced computed tomography (CT) four months after surgery suggested local relapse. Sunitinib was administered for 9 months, which led to complete response (CR).ConclusionsThis study presented the case of sunitinib therapy for renal cancer in the native kidney after renal transplantation. The therapeutic efficacy and safety for such cases should be discussed.

Angiosarcoma in an arteriovenous fistula after kidney transplantation: Case report and review of treatment options

“…Sunitinib is a multitargeted tyrosine kinase inhibitor that inhibits the VEGF receptor. Several case reports describe successful treatment of angiosarcoma with sunitinib 2,30‐32 . One phase II trial of sunitinib in soft tissue sarcomas (with exclusion of gastrointestinal stromal tumors) included two patients with angiosarcoma.…”

“…Several case reports describe successful treatment of angiosarcoma with sunitinib. 2,[30][31][32] One phase II trial of sunitinib in soft tissue sarcomas (with exclusion of gastrointestinal stromal tumors) included two patients with angiosarcoma. None of these patients had a response.…”

Renal Cell Carcinoma and Kidney Transplantation: A Narrative Review

“…No treatment, an introduction of mTOR inhibitor, and/or therapy with TKI are all valid options. No trial evidence exists for TKI in KTRs, few case reports show effect in localized 99,100 and metastatic [101][102][103] disease, though as for immune checkpoint inhibitors, toxicity may limit treatment. 104,105 Based on the current available data, we present our suggested recommendations as an overview in Figure 3 and with details in Table 3.…”